| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Gain from sale of priority review voucher, net | - | 152,366 | - | - |
| Income (loss) before income taxes | -20,358 | 124,345 | - | - |
| Income tax (benefit) expense | -15,197 | 15,512 | - | - |
| Net (loss) income | -5,161 | 108,833 | -12,029 | -30,269 |
| Change in unrealized gains related to available-for-sale debt securities | 55 | 22 | -75 | 50 |
| Comprehensive (loss) income | -5,106 | 108,855 | -12,104 | -30,219 |
| Basic | 54,242,507 | 52,524,510 | 49,778,801 | 48,081,758 |
| Basic (loss) income per common share | -0.1 | 2.07 | -0.24 | -0.63 |
| Dilutive | 54,242,507 | 66,640,620 | 49,778,801 | 48,081,758 |
| Dilutive (loss) income per common share | -0.1 | 1.71 | -0.24 | -0.63 |
ABEONA THERAPEUTICS INC. (ABEO)
ABEONA THERAPEUTICS INC. (ABEO)